Save

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

PHASE2RECRUITING

The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS.

Simpliy with AI

Study details:

KER-050 is a therapeutic protein designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias including anemia and thrombocytopenia in patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Diagnosis of MDS according to World Health Organization (WHO)/French American British (FAB) classification that meets Revised International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate risk disease.

< 5% blasts in bone marrow.

Peripheral blood white blood cell count <13,000/µL.

Anemia defined as: In non-transfused participants, having received no red blood cell (RBC) transfusions within 8 weeks Hgb concentration ≤ 10.0 g/dL OR In LTB participants, having received 1 to 3 units RBCs for Hgb ≤ 9.0 g/dL within 8 weeks OR In HTB participants, having received ≥ 4 units of RBCs for Hgb ≤ 9.0 g/dL within 8 weeks

Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (if related to anemia.

Females of child-bearing potential and sexually active males must agree to use effective methods of contraception.

Exclusion criteria

Any active infection requiring parenteral antibiotic therapy within 28 days prior to Cycle 1 Day 1 or oral antibiotics within 14 days of Cycle 1 Day 1.

Diagnosis of secondary MDS (i.e., MDS known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases).

Vitamin B12 deficiency.

Prior treatment with azacitidine, decitabine, lenalidomide, luspatercept, or sotatercept.

Treatment within 28 days prior to Cycle 1 Day 1 with: Erythropoiesis stimulating agent (ESA) OR Granulocyte colony-stimulating factor (G-CSF) OR Granulocyte-macrophage colony-stimulating factor (GM-CSF)

Iron chelation therapy if initiated within 8 weeks prior to Cycle 1 Day 1.

Vitamin B12 therapy within 8 weeks prior to Cycle 1 Day 1.

Treatment with another investigational drug or device or approved therapy for investigational use ≤ 28 days prior to Cycle 1 Day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to Cycle 1 Day 1, whichever is longer.

Platelet count > 450 x 10*9/L or < 30 x 10*9/L.

Transferrin saturation < 15%.

Ferritin < 50 µg/L.

Folate < 4.5 nmol/L (< 2.0 ng/mL).

Vitamin B12 < 148 pmol/L (< 200 pg/mL).

Estimated glomerular filtration rate (GFR) < 40 mL/min/1.73 m2 (as determined by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI].

Pregnant or lactating females

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2020-08-19

Primary completion: 2025-06-30

Study completion finish: 2025-11-30

Study type

TREATMENT

Phase

PHASE2

Trial ID

NCT04419649

Intervention or treatment

DRUG: KER-050

Conditions

• Myelodysplastic Syndromes
• Cytopenia

Image related to Myelodysplastic Syndromes

Condition: Myelodysplastic Syndromes, Cytopenia
DRUG: KER-050
Tweed Heads, New South Wales, Australia and more
Sponsor: Keros Therapeutics, Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

The Tweed Hospital

Research sites nearby

Select from list below to view details:

The Tweed Hospital
Tweed Heads, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Townsville University Hospital
Douglas, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: KER-050 Cohort 1 Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.	DRUG: KER-050 KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
EXPERIMENTAL: KER-050 Cohort 2 Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.	DRUG: KER-050 KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
EXPERIMENTAL: KER-050 Cohort 3 Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.	DRUG: KER-050 KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
EXPERIMENTAL: KER-050 Cohort 4 Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.	DRUG: KER-050 KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
EXPERIMENTAL: KER-050 Cohort 5 Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.	DRUG: KER-050 KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
EXPERIMENTAL: KER-050 Dose Confirmation Cohort Participants to receive KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.	DRUG: KER-050 KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence of adverse events (AEs) and serious adverse events (SAEs).	Type, frequency, severity of AEs and relationship of AEs to KER-050	From treatment initiation to end of study, approximately 2 years

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Maximum concentrations of KER-050	Pharmacokinetics of KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Erythroid response in low-transfusion burden (LTB) and high-transfusion burden (HTB) participants.	In LTB participants, the proportion of participants who have a hemoglobin increase of ≥ 1.5 g/dL from Baseline for ≥ 14 days (in the absence of RBC transfusions). In HTB participants, the proportion of participants having a reduction of ≥ 50% or ≥ 4 RBC units transfused compared to pretreatment over an 8-week period.	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Incidence of progression to higher risk MDS or AML per World Health Organization 2016 criteria	Change in baseline laboratory assessments prior to treatment with KER-050 and after treatment with KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Incidence of progression to higher risk MDS or AML per World Health Organization 2016 criteria	Change in baseline bone marrow assessments prior to treatment with KER-050 and after treatment with KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Modified 2006 International Working Group (IWG) Hematologic Improvement Erythroid (HI-E) response	In LTB participants, the proportion of participants with an increase of ≥ 1.5 g/dL from pretreatment hemoglobin during any 8-week period on study compared to Baseline. In HTB participants, the proportion of participants having a reduction by ≥ 4 units of RBCs transfused (for a hemoglobin ≤ 9.0 g/dL) during any 8-week period on study, compared with the 8-week period prior to study Cycle 1 Day 1.	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Mean change from baseline in hemoglobin	Change in baseline hemoglobin prior to treatment with KER-050 and after treatment with KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Time to erythroid response and modified 2006 IWG HI-E response	Time to erythroid response prior to treatment with KER-050 and after treatment with KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Duration of erythroid response and modified 2006 IWG HI-E response	Duration of erythroid response prior to treatment with KER-050 and after treatment with KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Frequency of red blood cell (RBC) transfusions and rate of RBC transfusion independence ≥ 8 weeks	Frequency and rate of RBC transfusions prior to treatment with KER-050 and after treatment with KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years
Change from Baseline in RBC counts and reticulocytes	Change in baseline RBC counts and reticulocytes prior to treatment with KER-050 and after treatment with KER-050	Measured at multiple timepoints over the course of study from study day 1 to end of study, approximately 2 years

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes